Know Cancer

forgot password

Clinical Investigation of the ProACT Adjustable Continence Therapy for Treatment of Post-Prostatectomy Stress Urinary Incontinence

Phase 2/Phase 3
45 Years
Open (Enrolling)
Urinary Incontinence

Thank you

Trial Information

Clinical Investigation of the ProACT Adjustable Continence Therapy for Treatment of Post-Prostatectomy Stress Urinary Incontinence

The study is a prospective, non-randomized multi-center investigation. Multiple
measurements using 24 hour pad weight and pad count, validated questionnaires, voiding
diaries will be used to evaluate the achievement of the study objectives. Subjects will be
followed for a minimum of 18 months following implantation. Subjects will be requested to
continue annual follow-ups through the FDA approval.

The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive
surgical procedure in up to 109 male patients. The ProACT device is designed to treat men
who have stress urinary incontinence arising from intrinsic sphincter deficiency following
an operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two
adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress

The results will be analyzed to demonstrate the effects of the device as well as its
associated risks. Therapeutic success will be based on whether patients demonstrate at
least a 50% reduction in pad weight at 18 months follow-up compared to the pad weight
results at baseline.

Inclusion Criteria:

- Undergone either a radical prostatectomy, transurethral resection of the prostate or
other prostate surgery at least 12 months prior without radiation therapy

- Demonstrate primary stress urinary incontinence

- Male subjects at least 45 years of age

- Willing and able to undergo surgical implantation of the ProACT devices

- Willing and able to comply with the follow-up requirements

- Willing and able to forego any other surgical urinary incontinence treatments while
participating in the study

- Willing and able to sign the informed consent

- Positive 24 hour pad weight tests (greater than or equal to 8 gram pad weight
increase demonstrated in two 24-hour pad weight tests)

- Experiences at least 3 incontinence episodes per day during two baseline voiding

- Negative Urine culture

- No recurrent stricture at the anastamosis

- No known urogenital malignancy other than previously treated prostate cancer

- Physician determines subject to be suitable surgical candidate

Exclusion Criteria:

- Primarily Urge incontinence

- Detrusor instability or over-activity

- Residual volume greater that 100 ml or greater than 25% of the total bladder capacity
after voiding.

- Subject has/had or is suspected of having bladder cancer

- History of recurrent bladder stones

- Neurogenic bladder that is atonic or has detrusor sphincter dyssynergia

- Known hemophilia or a bleeding disorder

- Abnormal PSA, according to sites laboratory standards, unless further investigation
confirms no underlying prostate malignancy.

- Known sever contrast solution allergy

- Has a genitourinary mechanical prosthesis other than previous sling procedure (e.g.,
Artificial Urinary sphincter, implantable penile prosthesis)

- Has a urethral stricture that prevents passage of an 18 F cystoscope or has had more
than one urethrotomy

- Undergone bulking procedure within 6 months of the baseline assessment

- Subject is currently enrolled or plans to enroll in another device or drug clinical

- Subject is currently using an indwelling catheter or condom catheter for treatment of
incontinence and is not willing to discontinue use at least 4 weeks prior to baseline

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Primary Efficacy: Demonstrate the efficacy of the ProACT device in reducing incontinence as measured by the 24-hour pad weight at 18 months compared to baseline. A subject is a success if he demonstrates a 50% reduction.

Outcome Description:

24 hour pad weight

Outcome Time Frame:

6wk, 6 mo, 12 mo, 18 mo, 2 yr, annually after

Safety Issue:


Principal Investigator

Tim Cook, Ph.D

Investigator Role:

Study Director

Investigator Affiliation:

Uromedica, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

August 2005

Completion Date:

March 2013

Related Keywords:

  • Urinary Incontinence
  • Urinary Incontinence
  • Urinary Incontinence
  • Urinary Incontinence, Stress



University of Arizona Tucson, Arizona  85724
Kansas City Urology Care Kansas City, Missouri  64131
Kaiser Permanente-Los Angeles Los Angeles, California  90027
The Pelvic Clinic Pembroke Pines, Florida  33028
Indian River Urology Vero Beach, Florida  32960
Urological Surgeons Kankakee, Illinois  60901
Metro Urology St. Paul, Minnesota  55102